Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access


Login To Get Involved!

Forgot your username?

Forgot your password?


Join Us At EiR Now!

DNRS Roof Banner


New DNRS 2.0 Available NOW! Improved via Research & Patient Feedback.

Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Fibromyalgia syndrome in the general population of France: A prevalence study





Joint Bone Spine. 2008 Sep 24. [Epub ahead of print]


Fibromyalgia syndrome in the general population of France: A prevalence study.


Bannwarth B, Blotman F, Roué-Le Lay K, Caubère JP, André E, Taïeb C.
Rheumatology Department, University Hospital Pellegrin, Bordeaux, France.



OBJECTIVE: To estimate the prevalence of fibromyalgia (FM) syndrome in the French general population.


METHODS: A validated French version of the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ) was administered via telephone to a representative community sample of 1014 subjects aged over 15 years, selected by the quota method. A positive screen was defined as: (1) meeting the 4-pain criteria alone (LFESSQ-4), or (2) meeting both the 4-pain and 2-fatigue criteria (LFESSQ-6). To estimate the positive predictive value of LFESSQ-4 and LFESSQ-6, this questionnaire was submitted to a sample of rheumatology outpatients (n=178), who were then examined by a trained rheumatologist to confirm or exclude the diagnosis of FM according to the 1990 American College of Rheumatology criteria. The prevalence of FM in the general population was estimated by applying the predictive positive value to eligible community subjects (i.e., positive screens).


RESULTS: In the community sample, 9.8% and 5.0% screened positive for LFESSQ-4 and LFESSQ-6, respectively. Among rheumatology outpatients, 47.1% screened positive for LFESSQ-4 and 34.8% for LFESSQ-6 whereas 10.6% were confirmed FM cases. Based on positive screens for LFESSQ-4, the prevalence of FM was estimated at 2.2% (95% CI 1.3-3.1) in the French general population. The corresponding figure was 1.4 % (95% CI 0.7-2.1) if positive screens for LFESSQ-6 were considered.


CONCLUSION: Our findings suggest that FM is also a major cause of widespread pain in France since a point prevalence of 1.4% would translate in approximately 680,000 patients.


PMID: 18819831 [PubMed - as supplied by publisher]









Please Help Support EiR with a Positive Google Review!

Review 'The Environmental Illness Resource' (EiR) on Google


If you like EiR and / or enoyed this content; please help us keep going by leaving a Positive Google Review:
Review EiR on Google NOW!

P.S. This is entirely secure, we collect no data other than what is freely available from Google and you can remain anonymous!


Related Articles:


Mold Testing & Sanitizer:







  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner

View the very BEST Environmental Illness Videos!

1. Your Health is Governed by Your Environment | Prof. BM Hegde | TEDx Talk

2. Demystifying Multiple Chemical Sensitivity

3. Social Determinants of Health - An Introduction